Elevated STIL predicts poor prognosis in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

Elevated STIL predicts poor prognosis in patients with hepatocellular carcinoma

Published:2023-02-17 Issue:7 Volume:102 Page:e33004
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Song Huangqin¹,Zhao Haichao¹,Chen Changzhou²,Zhang Donglin¹,Wang Xiaoxiao¹,He Jiefeng¹³⁴^ORCID

Affiliation:

1. Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China

2. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education; Institute of Biomedical Sciences, Fudan University, Shanghai, China

3. Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China

4. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

Overexpression of SCL/TAL1 interrupting locus (STIL) has been observed in various cancer types. However, the clinical significance of STIL in hepatocellular carcinoma (HCC) remains unknown. Cox regression and Kaplan–Meier survival analyses were performed to evaluate the prognostic value of STIL. Go and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were also carried out. Immune infiltrates analyses were conducted based on TIMER (Tumor Immune Estimation Resource) and GAPIA databases. STIL expression was highly expressed in HCC tissues, based on multiple databases. KEGG and GO enrichment analysis showed STIL-related to tumorigenesis and progress. Furthermore, STIL was significantly correlated with immune infiltration. STIL serves as a biomarker for the prediction of patient survival.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference32 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Sung;CA Cancer J Clin,2021

2. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.;Allemani;Lancet,2018

3. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.;Fujiwara;J Hepatol,2018

4. Recurrence patterns after anatomic or parenchyma-sparing liver resection for hepatocarcinoma in a western population of cirrhotic patients.;Famularo;Ann Surg Oncol,2018

5. Cell-cycle-regulated expression of STIL controls centriole number in human cells.;Arquint;J Cell Sci,2012